Targeted delivery vehicles for future-ready therapeutics
Optimer-drug conjugates offer highly specific targeting vehicles for the delivery of therapeutic agents to selected cell populations and tissues for the treatment of disease. The ability to select Optimers that discriminate between cell types, including organ-specific and healthy vs diseased cell populations, allows for site-specific therapeutic targeting and delivery.
Optimers can be used to deliver a wide variety of cargo and toxic payloads, including chemotherapeutic agents, siRNA, synthetic virions and synthetic genes. As the aptamer library can be prepared with the drug and linker conjugate in place, we are able to select for Optimers with the drug in situ, to ensure optimal stability and performance of the end-stage therapeutic. Additionally, the ability to specifically modify Optimer-drug conjugate ratios via site-specific labelling and the addition of extension bases for further conjugation allows optimisation of therapeutic performance and dosing.
Proprietary selection methods allow us to ensure the selected Optimers are taken up by the target cell population in a highly selective manner. The small size of Optimers offers increased tissue penetration for therapeutic delivery to solid tumours and hard to reach targets. The inherent low immunogenicity exhibited by Optimers, overcomes the need for downstream humanisation of the molecule, potentially increasing the speed of therapeutic development.
- High tumour uptake: Optimers small molecular size allows improved tissue penetration for targets that are difficult to reach
- Optimised formatting and modification: site-specific functionalisation with a variety of linker types and excellent tox profile
- Security of supply: Synthetic production processes simplifies Optimer-drug conjugate development
- Inert format: Optimers are non-immunogenic and do not require humanisation
- Selective cell/tissue targeting: biodistribution flexibility and reduced off-target effects
To see who we are currently working with and learn about our ongoing therapeutic collaborations, please see our Pipeline.